Navigation Links
Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Date:12/14/2009

NEW HAVEN, Conn., ,Dec. 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that it had received a complete response letter from the U.S. Food and Drug Administration ("FDA") related to its New Drug Application ("NDA") for Onrigin(TM) (laromustine) injection submitted in February 2009. The letter indicates that the FDA cannot approve the Company's NDA in its present form and provides recommendations to address remaining issues.

Alan Kessman, Chief Executive Officer, responded, "Based on the previously disclosed results of the Oncologic Drug Advisory Committee Meeting in September, we expected that the FDA would ask us to conduct an additional randomized study of Onrigin(TM) prior to approval. The complete response letter confirms our expectation."

The complete response letter advised that the Company complete a randomized study or studies to define the efficacy and safety of Onrigin(TM) in the patient population proposed for the indication, and that the study or studies should be designed to demonstrate a survival benefit that is clearly attributable to Onrigin(TM) with an acceptable safety profile in a well-characterized patient population. In addition to clinical and statistical recommendations, the letter also addressed clinical pharmacology and manufacturing issues. The complete response letter also requested that the Company provide an update on Onrigin(TM) safety information when the issues above had been addressed.

In connection with its previously disclosed review of strategic alternatives, the Company also announced that it had terminated its agreement with Merriman Curhan Ford & Co. and that it had retained Roth Capital Partners, LLP as its advisor to assist the Company in its evaluation of strategic alternatives. As previously announced, the Company does not have sufficient capital to fund a new randomized study of Onrigin(TM) and if the Company
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Unichem Pharmaceuticals ( USA ), ... tablets 25 mg 1000-count bottle to the consumer level. ... due to the identification of a Clopidogrel tablet found ... The risk associated with mistakenly taking a Clopidogrel tablet ... of experiencing Clopidogrel,s side effects which include bleeding and/or ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Dale ... the United States, will speak at the International Cannabis Professionals Expo held at the ... , The International Cannabis Professionals Expo is the largest medical cannabis ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... 30, 2015 , ... OSF Healthcare System has been recognized as ... Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive year for ... The Sisters of the Third Order of St. Francis . , Health data security ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca ... on the go. With no water needed, the refreshing berry-flavored tablets are the ... to get the natural ingredients that may help with body detoxification, protection and ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, ... than 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... East the health service is losing more than ?50m because ... ,Despite years of similar complaint by NHS managers the situation ... Hospital in Huntingdon said: ‘Some people do not turn up ... cause us a lot of problems in lost capacity and ...
... Researchers have established that white blood cells, derived from ... can be exploited// in the development of novel forms ... other mice with cancer, it was found to confer ... ,This study for the first time highlights the presence ...
... students in north Bihar's Muzaffarpur and Darbhanga towns staged ... blocks both in support // as well as in ... technical institutions of the country. Students ... Muzaffarpur burnt the effigy of Union HRD minister Arjun ...
... to a study in UK it was found that de- ... of Health analyzed 1,383 people with Naltrexone//. This drug blocks ... reported in the Journal of the American Medical Association. ... thereby help in reducing the number of alcohol addicts. The ...
... a generally accepted fact that the doses given to ... is not always clear, how much is enough for ... Center shows that making the dosage a computerized affair ... ,An online infusion calculator and a computerized ...
... pulmonary fibrosis (IPF) is a disease whose cause and cure ... for it till date//. It is a lung disease characterized ... of the entire organ (lung). Statistics show that ... cases are diagnosed every year. Ten years ago Jean ...
Cached Medicine News:Health News:Tumor Resistant Mice Point To Novel Cancer Treatments 2Health News:Dispensing Drug Dosage To Children Through Computers 2Health News:Dispensing Drug Dosage To Children Through Computers 3Health News:Dispensing Drug Dosage To Children Through Computers 4Health News:Lesser Know Facts about Idiopathic Pulmonary Fibrosis (IPF) 2
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
... The Directigen™ Meningitis Individual Tests ... tests for the direct qualitative ... influenzae type b, S. pneumoniae, ... Escherichia coli K1 in cerebrospinal ...
Medicine Products: